<DOC>
	<DOCNO>NCT01631552</DOCNO>
	<brief_summary>The primary objective evaluate safety tolerability IMMU-132 single agent administer 3-week treatment cycle 8 cycle , previously treat patient advanced epithelial cancer.The secondary objective obtain initial data concern pharmacokinetics , immunogenicity , efficacy dose regimen . IMMU-132 target TROP-2 antigen express variety cancer . The antibody , RS7 , attach SN38 , active metabolite irinotecan . This plan multi-center study . In Phase II , 130 patient ( assessable ) triple-negative breast cancer , 100 patient ( assessable ) non-small cell small-cell lung cancer 50 patient ( assessable ) per cancer type include protocol study 10 mg/kg dose .</brief_summary>
	<brief_title>Phase I/II Study IMMU-132 Patients With Epithelial Cancers</brief_title>
	<detailed_description>This Phase I/II , open-label study IMMU-132 previously treat patient advanced epithelial cancer , include ovarian , breast , prostate ( hormone refractory ) , lung ( non-small cell small cell ) , head &amp; neck ( squamous cell ) , esophageal , gastric , colorectal , pancreatic , hepatocellular , renal ( clear cell ) , endometrial , cervical , urothelial , thyroid cancer glioblastoma multiforme . Patients receive IMMU-132 administer once-weekly first 2 week 3-week treatment cycle . Patients may receive maximum total 8 cycle ( 16 dos ) , patient partial response stable disease time , patient achieve objective response relapse discontinue treatment , may continue treat base physician discretion . Treatment continue unacceptable toxicity progression disease . Both safety efficacy assess .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma , Follicular</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Male female patient , &gt; 18 year age , able understand give write informed consent . Histologically cytologically confirm epithelial cancer one follow type : Colorectal Gastric adenocarcinoma Esophageal cancer Hepatocellular carcinoma Nonsmall cell lung cancer Small cell lung cancer Ovarian epithelial cancer Cervical Cancer Endometrial Cancer Breast cancer Hormonerefractory prostate cancer Pancreatic ductal adenocarcinoma Head neck cancer squamous cell Renal cell cancer ( clear cell ) Urothelial cancer Glioblastoma multiforme Follicular thyroid cancer ( Note : Confirmation Trop2 expression immunohistology mean require , Sponsor request tissue specimens archived material determination Trop2 expression . ) Stage IV ( metastatic ) disease . Refractory relapse least one prior standard therapeutic regimen ( Appendix 1 list approve standard chemotherapeutic agent cancer type . Patients receive approved standard treatment cancer must inform alternative receive IMMU132 available prior consent participate trial . ) Adequate performance status ( ECOG 0 1 ) Expected survival &gt; 6 month . Measurable disease CT MRI . At least 2 week beyond treatment ( chemotherapy , investigational drug include small molecular inhibitor , immunotherapy and/or radiation therapy ) major surgery recover acute toxicity Grade 1 less ( except alopecia ) . At least 2 week beyond high dose systemic corticosteroid ( however , low dose corticosteroid &lt; 20 mg prednisone equivalent daily permit ) . Adequate hematology without ongoing transfusional support ( hemoglobin &gt; 9 g/dL , ANC &gt; 1,500 per mm3 , platelet &gt; 100,000 per mm3 ) . Adequate renal hepatic function ( creatinine ≤ 2.0 x IULN , bilirubin ≤ 1.5 IULN , AST ALT ≤ 3.0 x IULN 5 x IULN know liver metastasis ) . Otherwise , toxicity study entry &lt; Grade 1 . •Women pregnant lactating . Women childbearing potential fertile men unwilling use effective contraception study conclusion 12week posttreatment evaluation period . Patients Gilbert 's disease . Patients brain metastasis enrol treat , nonprogressive brain metastasis highdose steroid ( &gt; 20 mg prednisone equivalent ) least 4 week . Presence bulky disease ( define single mass &gt; 7 cm great dimension ) . Patients mass 7 cm , otherwise eligible , may consider enrollment discussion approval medical monitor . Patients active ≥ grade 2 anorexia , nausea vomiting , and/or sign intestinal obstruction . Patients nonmelanoma skin cancer carcinoma situ cervix eligible , patient prior malignancy must least 3year diseasefree interval . Patients know HIV positive , hepatitis B positive , hepatitis C positive . Known history unstable angina , MI , CHF present within 6 month clinically significant cardiac arrhythmia ( stable atrial fibrillation ) require antiarrhythmia therapy . Known history clinically significant active COPD , moderatetosevere chronic respiratory illness present within 6 month . Prior history clinically significant bleeding , intestinal obstruction , GI perforation within 6 month initiation study treatment . Infection require intravenous antibiotic use within 1 week . history anaphylactic reaction irinotecan ≥ Grade 3 GI toxicity prior irinotecan , Other concurrent medical psychiatric condition , Investigator 's opinion , may likely confound study interpretation prevent completion study procedure followup examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Colorectal ( CRC )</keyword>
	<keyword>Gastric adenocarcinoma ( GC )</keyword>
	<keyword>Esophageal cancer ( EC )</keyword>
	<keyword>Hepatocellular carcinoma ( HCC )</keyword>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>Small cell lung cancer ( SCLC )</keyword>
	<keyword>Ovarian epithelial cancer ( OEC )</keyword>
	<keyword>Triple-negative breast cancer ( TNBC )</keyword>
	<keyword>Hormone-refractory prostate cancer ( HRPC )</keyword>
	<keyword>Pancreatic ductal adenocarcinoma ( PDC )</keyword>
	<keyword>Head neck cancers- squamous cell ( SCCHN )</keyword>
	<keyword>Renal cell cancer -clear cell ( RCC )</keyword>
	<keyword>Bladder cancer</keyword>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Cervical Cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic non-triple negative breast cancer</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Follicular thyroid cancer</keyword>
</DOC>